What ZEINCRO Group does

ZEINCRO Group is a privately held contract research organisation (CRO) headquartered in Sofia, Bulgaria, that provides clinical research services with a regional focus on Central and South-Eastern Europe. The company was founded in 1998 and currently operates with a headcount in the 101-250 range, placing it in the mid-sized tier of European CROs. Its self-described positioning is that of a regional specialist, suggesting it serves pharmaceutical and biotechnology sponsors running clinical trials that require country coverage, investigator networks, and regulatory navigation across multiple CEE jurisdictions rather than as a global full-service provider.

The company's core offering falls within the clinical research services value chain, which typically includes clinical trial management, site monitoring, regulatory affairs, pharmacovigilance, and biometrics support for sponsor-led studies. Specific service lines, therapeutic area depth, technology platforms, and proprietary tooling are not described in the available source data, and the company's own web property currently resolves to a cPanel default hosting error page, limiting the ability to verify current product detail. There is no information in the source material regarding its technology stack, electronic data capture systems, or any differentiated operating methodology.

ZEINCRO's revenue mechanics are likewise not disclosed in the source data; pricing model, contract structures (e.g., FTE-based, fee-for-service, milestone-based), customer segmentation (large pharma vs. mid-cap biotech vs. academic sponsors), and go-to-market approach are all unspecified. The firm has no recorded funding rounds, M&A activity, leadership changes, partnerships, or compliance certifications in the available data. The company's contact details indicate a generic webmaster channel ([email protected]) rather than a commercial contact, and no named customers, awards, or industry recognitions are documented. Given the data limitations, any assessment of ZEINCRO's current commercial performance must rely on industry benchmarks rather than primary disclosure.

Name

ZEINCRO Group

Website

https://zeincro.com

Company type

Private

Founded year

1998

Headcount range

101–250 employees

Short description

ZEINCRO Group is a Bulgaria-based contract research organisation, founded in 1998, that provides clinical research services to pharmaceutical and biotech sponsors with a regional focus on Central and South-Eastern Europe.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Contract research
• Clinical trials
• Pharmaceutical services
• Medical research
• Biotech services

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Core offering

ZEINCRO is a contract research organisation (CRO) specialising in clinical research services across Central and South-Eastern Europe. The company delivers outsourced clinical research operations to pharmaceutical, biotechnology, and medical device sponsors operating in the region.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Research Organisation Services

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO with deep European operations covering Phase II-IV across multiple therapeutic areas. Comparable to ZEINCRO as a mid-tier clinical CRO with European regional strength.
• PSI CRO: Founded in Ukraine and now headquartered globally, PSI is a mid-sized clinical CRO with strong roots in the Central and Eastern European region. It is directly comparable to ZEINCRO as another regionally rooted CRO offering Phase I-IV clinical trial services across CEE and beyond.
• Medpace: Medpace is a U.S.-headquartered, mid-to-large clinical CRO with established European operations and a science-led operating model. Comparable to ZEINCRO in the clinical CRO service category and as a peer on mid-sized sponsor contracts using European sites.
• Ergomed (now part of Clinipace Worldwide / acquired by Anglo-African): Ergomed was a mid-sized clinical CRO with specialty therapeutic expertise (notably oncology and rare disease) and a strong European footprint. ZEINCRO's regional European clinical CRO profile makes Ergomed a closely comparable mid-tier specialist peer.

Broad incumbents

• Parexel International: Parexel is a large global CRO with significant European clinical operations and a strong presence in CEE countries for Phase II-IV trials. Comparable to ZEINCRO in the clinical CRO service category serving biopharma sponsors across multiple therapeutic areas.
• Clario: Clario is a clinical trial technology and endpoint services company with deep European trial operations post its merger of Bioclinica, ERT, and Merge. Comparable to ZEINCRO as a clinical-trial services provider with European delivery capabilities, particularly on technology-enabled study execution.
• IQVIA: IQVIA is the largest global CRO and clinical technology provider, with established operations across the CEE region. Comparable to ZEINCRO as the dominant incumbent clinical CRO whose regional trial delivery capabilities overlap with ZEINCRO's specialized footprint.
• Syneos Health: Syneos Health is a leading global clinical CRO (now publicly taken private) with European clinical operations. Comparable to ZEINCRO in the clinical CRO service category serving biopharma sponsors across multiple countries.
• Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a large global CRO with central lab and clinical trial services across Europe. Comparable to ZEINCRO as a full-service clinical CRO with multi-country European trial delivery capabilities, though significantly larger and more diversified.
• ICON plc: ICON is one of the largest global CROs post its PRA Health Sciences merger, with extensive Eastern European site networks. Comparable to ZEINCRO as a clinical CRO competing for sponsor trials across European geographies, though at vastly greater scale.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/zeincro

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZEINCRO Group